PolyPid

Company Overview

Snapshot

Founded in February 2008, PolyPid operates with 51–200 employees and has raised over $239.24 million across 15 funding rounds from 8 investors. The company went public on NASDAQ in June 2020, marking a significant milestone in its journey to commercialize its drug delivery technologies.

Business overview

PolyPid is a late-stage biopharmaceutical company dedicated to improving surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This technology enables the precise, controlled, and prolonged release of therapeutics, delivering drugs at optimal rates over extended durations. The company's lead product candidate, D-PLEX100, is currently in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. Additionally, PolyPid is developing OncoPLEX, which is in preclinical testing for treating solid tumors, including glioblastomas, operating within the Health Tech & Life Sciences sector, specifically focusing on drug delivery and pharmaceuticals.

Strategic signal

PolyPid is actively preparing for key industry engagements, with plans to present its positive Phase 3 SHIELD II topline results at the 2025 American College of Surgeons Clinical Congress and participate in the 27th Annual H.C. Wainwright Global Investment Conference in September 2025. These upcoming presentations signal the company's progress in clinical development and its efforts to engage with the investment community, indicating potential for further validation and strategic partnerships.

Company Intelligence Q&A

What is PolyPid's primary technology?

PolyPid's core technology is PLEX (Polymer-Lipid Encapsulation matriX), which allows for the locally administered, controlled, and prolonged release of therapeutics, enabling precise drug delivery over durations ranging from days to months.

When did PolyPid go public?

PolyPid went public on NASDAQ in June 2020.

What is the status of PolyPid's lead product candidate, D-PLEX100?

D-PLEX100 is currently in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.

Has PolyPid received any recent regulatory eligibility?

In September 2022, PolyPid announced its eligibility for the European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the prevention of surgical site infections in abdominal surgery.

What was a significant recent financial event for PolyPid?

In January 2024, PolyPid announced a private placement that generated $16 million in gross proceeds, with participation from investors including Rosalind Advisors.